预约演示
更新于：2026-10-23
Rifamycin Sodium
利福霉素钠
更新于：2026-10-23
概要
基本信息
原研机构 |
权益机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (2000-02-01), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C37H47NNaO12 |
InChIKeyURCDBMLCEGDNOK-NLYBMVFSSA-N |
CAS号14897-39-3 |
关联
15
项与 利福霉素钠 相关的临床试验NCT04026984
Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
This will be a double-blind comparative study, performed in pediatric subjects (Age 6-11) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.
开始日期2024-06-01 |
申办/合作机构 |
CTIS2023-506917-23-00
Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solution administered by enema to patients with mild to moderate left-sided ulcerative colitis
开始日期2024-04-19 |
申办/合作机构 |
NCT04027894
Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years
This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.
开始日期2024-01-01 |
申办/合作机构 |
100 项与 利福霉素钠 相关的临床结果
登录后查看更多信息
100 项与 利福霉素钠 相关的转化医学
登录后查看更多信息
100 项与 利福霉素钠 相关的专利（医药）
登录后查看更多信息
2,204
项与 利福霉素钠 相关的文献（医药）2026-12-01·JOURNAL OF PHARMACEUTICAL SCIENCES
Antibiotic-loaded microparticles for topical treatment of wounds: a scoping review
Review
作者: Ciffoni, Maria Cecília Negreiros ; Lazo, Raul Edison Luna ; Sari, Marcel Henrique Marcondes ; Trindade, Giovanna Araujo de Moraes ; Ferreira, Luana Mota ; Pontarolo, Roberto
This scoping review aimed to map the evidence on antibiotic-loaded microparticles developed as controlled-release systems for topical wound treatment. The review followed the JBI methodology and was reported in accordance with the PRISMA-ScR checklist. The most frequently investigated antibiotics were gentamicin (n = 4; 21.1%), ciprofloxacin (n = 3; 15.8%), and doxycycline (n = 3; 15.8%), followed by vancomycin, mupirocin, and rifamycin (n = 2; 10.5% each). Chitosan and gelatin were the most common matrices (n = 6; 31.6% each), followed by alginate (n = 3; 15.8%). Most systems were incorporated into wound dressings, scaffolds, hydrogels, patches, or used as powder. Excisional wounds were the most frequently evaluated model (n = 12; 63.2%), followed by infected wounds (n = 5; 26.3%), whereas burn and diabetic wound models were less investigated (n = 1, 5.3%). These findings suggest that antibiotic-loaded microparticles may act as multifunctional wound-care systems by combining infection control, controlled local antibiotic release, and support for wound healing.
2026-10-07·CLINICAL INFECTIOUS DISEASES
Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial
Article
作者: Rofail, Lydia M ; Barnes, David ; Cho, Jin-Gun ; Goldberg, Hazel ; Harrington, Zinta ; Gray, Timothy ; Ulbricht, Evan ; Fox, Gregory J ; Foo, SooWei ; Chang, Vicky W L ; Byrne, Anthony L ; Li, Qingbin
Abstract:
Background:
Treatment of tuberculosis infection (TBI) is a key pillar of the World Health Organization End TB Strategy. Two short-course rifamycin-based regimens—3 months of weekly isoniazid plus rifapentine (3HP) and 4 months of daily rifampicin (4RIF)—are widely recommended; however, they have not previously been directly compared in a randomized controlled trial. We compared treatment completion between 3HP and 4RIF among individuals with TBI.
Methods:
We conducted a multicenter, open-label, parallel-group randomized controlled trial across 7 tuberculosis clinics in Sydney, Australia, between July 2019 and June 2024. Participants of any age with TBI were randomized 1:1, stratified by site, to receive either weekly 3HP or daily 4RIF. All doses were self-administered. Participants in the 3HP group received weekly Short Message Service (SMS) adherence reminders; both groups received standard clinic follow-up. The primary outcome was treatment completion, defined as ingestion of ≥90% of prescribed doses. Analyses were conducted on an intention-to-treat basis.
Results:
A total of 210 participants were enrolled (106 assigned to 3HP and 104 to 4RIF). Treatment completion was significantly higher in the 3HP group (84.9%) than in the 4RIF group (65.4%; relative risk, 1.30 [95% confidence interval, 1.22–1.38]; P < .001). Adverse events of any grade occurred in 24.5% of participants receiving 3HP and 20.2% receiving 4RIF. No treatment-related deaths were reported.
Conclusions:
Weekly 3HP supported by SMS reminders achieved significantly higher treatment completion than daily 4RIF, with similar safety. These findings support broader implementation of 3HP to optimize adherence and outcomes in TBI treatment programs.
Clinical Trials Registration:
Australian New Zealand Clinical Trials Registry (ACTRN12618001672246).
2026-10-01·LANCET INFECTIOUS DISEASES
A rifamycin-free regimen for shortened tuberculosis treatment
Article
作者: Fu, Liang ; Deng, Guofang
221
项与 利福霉素钠 相关的新闻（医药）2026-10-23
10月23日，BioBAY园内上市企业丹诺医药宣布，其在研新药候选物利福喹酮（rifaquizinone，TNP-2092）通过关节腔内注射给药治疗人工关节感染（PJI）的多中心IIb期临床试验已完成首例患者入组。该试验旨在进一步评估TNP-2092在不进行清创或翻修手术的情况下治疗PJI的有效性、安全性和药代动力学特征，标志着这一潜在颠覆性新药产品的临床开发进入关键阶段。
PJI：亟待解决的重大未满足临床需求
人工关节感染是关节置换术后一种严重的并发症，可令原本成功的手术演变为医疗与个人的双重危机。美国每年新增PJI病例约45,000例，中国约22,000例，并且呈快速增长趋势。据估算，到2035年全球每年新增PJI病例将达到425,800例，其中86,500例在中国。由于细菌生物膜的形成导致传统抗菌药物的疗效显著降低，PJI的治疗面临极大挑战。目前，PJI的治疗以手术干预为主，单纯依靠抗菌药物治疗因失败率极高，临床上不予推荐。
目前PJI患者面临的治疗选择均为手术路径，但治疗效果并不理想：对于早期术后或急性血源性PJI，指南推荐施行清创、抗菌药物及假体保留手术方案（DAIR），但报道的失败率在30%以上；对于慢性PJI，则推荐进行二期翻修手术，该方案涉及多次手术、长期住院及术后数月的功能丧失，而失败率仍超过10%。PJI带来的经济负担极为沉重，美国每例患者的治疗费用通常超过39万美元。
全球首创三靶点新药，IIa期数据提供概念验证
TNP-2092是一款全球首创的三靶点抗菌新药候选物，由利福霉素和氟喹诺酮两种药效团通过偶联技术合成，能够同时作用于RNA聚合酶、DNA旋转酶和拓扑异构酶IV三个关键靶点，具有强效且均衡的三重杀菌机制。临床前研究表明，TNP-2092对包括MRSA和耐甲氧西林凝固酶阴性葡萄球菌在内的PJI相关葡萄球菌菌株表现出优异的体外和体内活性，且不是NorA或MepA等外排泵的底物，能够有效应对耐药菌感染。
此前，TNP-2092已在美国获得FDA授予的合格传染病产品（QIDP）、快速通道和孤儿药资格认定。
本次IIb期临床试验的启动，是基于IIa期概念验证临床试验取得的积极顶线结果。该项在中国开展的IIa期POC临床试验，评估了TNP-2092关节腔内注射（不进行清创或翻修手术）在早期术后、急性血源性或慢性PJI患者中的疗效与安全性。截至2026年7月1日数据锁定日的中期分析显示：在接受TNP-2092治疗的5例早期或急性PJI患者中，全部完成6个月随访，治疗成功率为100%（5/5）；其中4例完成12个月随访，治疗成功率亦为100%（4/4）。安全性方面，共9例患者纳入安全性分析，研究中未报告与TNP-2092相关的治疗期不良事件或严重不良事件。
IIa期临床试验主要研究者，新疆医科大学第一附属医院骨科中心主任曹力教授表示：“TNP-2092的IIa期概念验证临床试验取得了令人兴奋的顶线结果。人工关节感染是一个世界难题和未满足临床需求，TNP-2092有望成为治疗人工关节感染的颠覆性创新药物，替代目前以清创和置换手术为主的治疗方式。”
▌文章来源：丹诺医药
责编：何文正
审核：任旭
推荐阅读
上市企业丨信诺维：新型大环内酯类抗生素XNW26018片获批临床
上市企业丨亚盛医药：利生妥®治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）获突破性疗法认定
上市企业丨创胜医药：重磅产品TST001及其伴随诊断获国家发明专利，III期临床试验已获美、中、韩三国批准
2026-10-14
·信使轻舟
如果只看赛道，丹诺医药其实不像这几年资本市场最喜欢的Biotech。它没有ADC，没有双抗，没有CAR-T，也没有把AI写进公司名字，而是在做一个已经存在了几十年的领域：抗菌药。问题在于，抗菌药恰恰是一个看起来传统、实际上非常难做的赛道，因为一边是大量廉价仿制药把价格压得很低，另一边又是耐药、生物膜和复杂感染不断制造新的临床需求。丹诺真正押注的不是“再做一个更强的抗生素”，而是试图用多靶点偶联分子的方式，把两个甚至多个抗菌药效团做进同一个新分子里，让细菌同时面对多个杀伤机制，从而提高疗效并降低耐药出现的概率。
丹诺最接近商业化的产品是利福特尼唑TNP-2198，它最有意思的地方不是简单把利福霉素和硝基咪唑一起吃，而是把两种药效团通过化学结构稳定地连接成一个新的分子。利福霉素部分主要攻击细菌RNA聚合酶，阻断转录；硝基咪唑部分则可以在微需氧或厌氧环境中被还原激活，对DNA等产生损伤。早期结构和药理研究甚至发现，这个偶联分子的活性并不是两个旧药效果简单相加，它在一些耐药菌株中的活性可以明显高于两个母体药物的混合使用，因此丹诺所谓“多靶点偶联平台”至少不是一个纯粹的营销概念，而是真正存在药化和机制基础。
利福特尼唑选择的第一个大适应症是幽门螺杆菌，这个选择其实很聪明。幽门螺杆菌感染人数极大，又和胃炎、消化性溃疡以及胃癌风险直接相关，但几十年来治疗方式主要还是在已有抗生素之间排列组合。中国常见的铋剂四联方案通常需要同时使用多种药物，而且克拉霉素、甲硝唑等耐药问题越来越突出。丹诺的思路不是重新发明整个治疗体系，而是用一个专门针对幽门螺杆菌开发的新抗菌分子，把治疗方案重新压缩成利福特尼唑、阿莫西林和抑酸药组成的三联方案。
这条管线最重要的地方，是它已经不再停留在“早期数据看起来不错”。EVEREST-HP三期研究在中国40个中心完成，在主要mITT分析中，利福特尼唑三联方案的根除率达到92.0%，对照方案为87.9%，达到非劣效标准；同时治疗期间不良事件发生比例为37%，对照组为53%。在多重耐药菌亚组中，新方案的根除率也表现出一定优势。这个结果意味着利福特尼唑现在面对的最大问题已经不再是“它到底有没有药效”，而是监管能否批准、价格怎么定、医生是否愿意改变现有处方习惯，以及最终能不能进入医保并快速放量。
这也是为什么丹诺现在已经从研发公司开始进入真正困难的商业化阶段。利福特尼唑的上市申请已经在2025年被NMPA受理，2026版中国成年人幽门螺杆菌感染指南也已经把它作为具有临床应用前景的新型治疗药物纳入讨论。丹诺自己没有打算建立一个非常庞大的销售团队，而是把中国大陆、香港和澳门的商业推广交给远大生命科学，双方设置了最高7.75亿元的首付款及商业和销售里程碑安排。对于一家员工只有几十人的Biotech来说，这种策略很合理，因为幽门螺杆菌治疗覆盖的是大量消化科和基层患者，如果自己从零建立全国销售体系，资金消耗会非常大。
但这里也不能因为“92%的根除率”和“全球首创”就直接推导出这是一个超级大药。幽门螺杆菌现有治疗非常便宜，而且临床医生已经习惯了成熟的联合抗生素方案，新药即使疗效更好，也必须证明它的价格、依从性、安全性和耐药优势足以让医生换药。尤其如果进入医保以后价格被明显压低，患者数量很大并不自动等于利润空间很大。因此利福特尼唑真正的商业价值，取决于它能否把“一个更方便的新抗生素”升级成新的标准一线方案，而不是只在传统方案失败或者耐药患者中使用。
相比利福特尼唑，丹诺第二个核心产品利福喹酮TNP-2092反而可能拥有更大的想象空间，因为它打的是人工关节感染，也就是PJI。这个病最麻烦的地方不是没有抗生素，而是细菌会在人工关节表面形成生物膜，进入一种代谢很慢甚至近似休眠的状态。传统抗生素很难彻底穿透和清除这些细菌，所以临床治疗往往不是“打一周抗生素”，而是清创、长期抗菌治疗，甚至把整个人工关节取出来，再进行一期或二期翻修手术。
如果一种药可以在不更换人工关节甚至不做清创手术的情况下把感染真正清掉，那么它改变的就不是一个抗生素品种，而可能直接改变PJI的治疗路径。TNP-2092正是在赌这件事，它把多个抗菌作用机制整合在一个分子中，同时通过关节腔内给药把高浓度药物直接送到感染部位，希望对付生物膜以及其中难以清除的细菌。
2026年公布的IIa期概念验证结果非常亮眼，但也必须非常冷静地看。早期或急性PJI患者中，5名完成6个月随访的患者全部治疗成功，其中4名完成12个月随访的患者同样全部成功；慢性PJI患者只有2名，6个月时1名治疗成功，而且整个有效性分析集只有7个人。这个结果足以证明“非手术治疗PJI值得继续试”，但完全不足以证明药物已经能够稳定取代手术，因为样本量太小、没有大规模随机对照，而且早期PJI和慢性PJI本身就不是一个难度等级。真正决定这条管线价值的是已经启动的IIb期，以及未来更大规模研究能不能复制这个信号。
如果TNP-2092后面真的能够在随机对照研究中证明一部分PJI患者不需要翻修手术，那它的价值可能反而比幽门螺杆菌产品更高，因为它解决的是一个非常明确而且非常昂贵的临床痛点。对于医生和支付方来说，避免一次甚至多次复杂关节翻修手术所节约的成本巨大，因此这种药物即使定价远高于普通抗生素，也有更强的药物经济学理由。换句话说，利福特尼唑决定丹诺能不能很快产生销售收入，而利福喹酮更可能决定市场最终会把丹诺看成一家普通抗感染公司，还是一家真正拥有差异化平台能力的创新药公司。
丹诺的创始人马振坤也值得单独看，因为这家公司其实带有非常明显的创始人路线特征。他早年在雅培从事抗菌药研发，后来参与Cumbre Pharmaceuticals，在那里就开始研究多靶点抗菌分子和生物膜感染，之后又担任全球结核病新药研发联盟的首席科技官，2013年回国创立丹诺。换句话说，丹诺不是在某一轮抗菌药突然受到政策关注以后才临时进入这个赛道，而是创始人二十多年一直在做同一类问题，这种长期积累在Biotech里其实比“追热门靶点”更加值得注意。
公司本身也非常小。招股阶段公开数据只有大约50名员工，其中接近四分之三是研发人员，这意味着丹诺更接近一个高度外包、轻组织的研发公司，而不是已经拥有完整生产和销售体系的Biopharma。这样的结构优点是固定成本低、研发效率可能比较高，缺点则是公司对核心管理团队、合作方和外部CRO/CDMO依赖程度很高。至于员工福利、内部文化和实际工作强度，目前公开资料并不足以做可靠判断，因此这部分不能仅凭招聘网站几条评论就下结论。
资本层面上，丹诺已经完成了一次很大的身份变化。2026年5月22日，公司以75.70港元发行价登陆港交所18A，IPO总募资超过6亿港元；到2026年6月底，公司现金及现金等价物约7.15亿元人民币，上半年研发开支约3130万元，净亏损约6420万元，而且目前仍然没有产品销售收入。从现金消耗速度看，它短期并不是那种马上面临生存压力的Biotech，真正的问题是未来商业化启动和TNP-2092进入更大型临床以后，费用会不会快速上升。
从投资角度看，丹诺其实是一家非常典型的事件驱动型Biotech，现在市值大约在50多亿港元附近，市场实际上已经提前给了利福特尼唑获批以及TNP-2092进一步成功相当一部分预期。它并不能简单按照市盈率估值，因为现在没有收入和利润，更合理的逻辑应该是把两条核心资产分别做风险调整后的销售峰值估值，再加上早期管线和现金，同时扣除未来临床和商业化支出。
利福特尼唑的概率已经相对高，因为三期完成、NDA受理、指南开始关注，最大的未知逐渐从研发风险转成商业化风险；TNP-2092则恰好相反，目前临床概率仍然很低，但一旦IIb、III期继续证明“部分PJI可以不手术”，它的单个资产价值会发生非常剧烈的重估。因此这家公司未来最值得看的并不是每天的股价，而是两个完全不同性质的验证：第一个是利福特尼唑上市以后到底卖得怎么样，第二个是TNP-2092的小样本神奇数据能不能在大样本里复制。
这里还有一个容易被忽略的风险，就是抗菌药本身的商业模式历史上并不好。新抗生素即使非常有效，医生往往为了延缓耐药而限制使用，医院采购和支付能力也不像肿瘤药那样可以轻松接受几十万元一年的价格，因此全球已经出现过多家抗菌药Biotech即使药物获批仍然经营困难的案例。丹诺的优势是它没有主要去做普通耐药菌感染，而是选择幽门螺杆菌和人工关节感染这些可以形成明确差异化治疗路径的适应症，但最终能不能摆脱“好药不赚钱”的抗菌药产业困境，仍然需要商业化数据证明。
所以丹诺真正值得研究的地方，不是它有一个所谓“全球首创”产品，而是它试图证明一种更底层的研发逻辑：当传统抗生素因为单靶点耐药、生物膜和药代限制无法解决问题时，把多个药效机制通过一个新分子重新组合，能不能做出比简单联合用药更加稳定的产品。如果利福特尼唑能够完成商业化验证，而利福喹酮又能在PJI中复制早期结果，那么丹诺就不仅仅拥有两款药，而是证明了它的多靶点偶联平台能够连续产生有临床差异化的资产。
反过来说，如果利福特尼唑获批以后销售不及预期，而TNP-2092的大样本数据又回归普通抗生素水平，那么这家公司目前的估值也会失去非常重要的支撑。丹诺现在最有意思的地方正好就在这个节点上：第一款药已经非常接近真正的市场检验，第二款药刚刚出现一个可能改变治疗方式、但样本又小得必须保持警惕的信号。
这不是一家已经被证明成功的公司，但它也已经过了只靠PPT讲故事的阶段。未来两三年，丹诺能不能从一家五十多人的研发型Biotech真正变成一家能够持续产生现金流和新产品的Biopharma，答案基本会由利福特尼唑的上市销售曲线和TNP-2092的IIb/III期数据共同决定。
临床3期抗体药物偶联物免疫疗法细胞疗法微生物疗法
2026-10-12
·微信
THE LANCET Infectious Diseases. Volume 26Number 7
柳叶刀·传染病学26卷 7期
https://www.thelancet.com/journals/laninf/issue/current
Editorial（社论）
1
Key facts about the Bundibugyo virus outbreak
本迪布焦病毒暴发核心事实
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p651
Comment（述评）
2
Treatment of multidrug-resistant Gram-negative infections: a stewardship imperative
多重耐药革兰阴性菌感染治疗：抗菌药物管理势在必行
Sarah Kabbani,L Clifford McDonald
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p652
3
Meningococcal disease, meningococcal vaccines, and the recent meningococcal outbreak in Kent, UK
脑膜炎球菌病、脑膜炎球菌疫苗与英国肯特郡近期脑膜炎球菌暴发
Shamez N Ladhani,Caroline Trotter,Ray Borrow,Gayatri Amirthalingam,Mary E Ramsay
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p653
Correspondence（读者来信）
4
Actionable sexual health education for HIV and STI prevention among LGBTQ+ youth in the USA
面向美国性少数青年、可落地实施的艾滋病与性传播疾病预防性健康教育
Jonah Segil,Matthew J Mimiaga
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e268
5
Effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalisation and death: a Danish nationwide cohort study
适配LP.8.1变异株的BNT162b2新冠疫苗预防新冠相关住院与死亡的有效性：丹麦全国队列研究
Christian Holm Hansen,Bolette Soborg,Morten Rasmussen,Ida Rask Moustsen-Helms,Palle Valentiner-Branth
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e269
6
Andes virus on a cruise ship: person-to-person transmission and an empty pipeline
游轮安第斯病毒疫情：人传人传播与药物储备空白
Oriol Mitjà
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e271
7
Bundibugyo Ebola: why preparedness still fails at the point of detection
本迪布焦埃博拉病毒：为何疫情初筛阶段防控体系仍存在短板
Thirumalaisamy P Velavan,Peter G Kremsner,Francine Ntoumi
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e273
8
Cross-border transmission of Ebola virus disease caused by Bundibugyo virus into Uganda, 2026
2026年本迪布焦埃博拉病毒病跨境传入乌干达疫情
Henry Kyobe Bosa,Misaki Wayengera,Atek Kagirita,Bernard Lubwama,Allan Muruta,Susan Nabadda,Andrew Nsawotebba,Charles Olaro,Diana Atwine,Jane Ruth Aceng
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e275
9
Bundibugyo virus disease outbreak in DR Congo: current trajectory and potential risk for a Pandemic Emergency
刚果民主共和国本迪布焦病毒病暴发：当前流行态势及构成国际关注突发公共卫生事件潜在风险
Marie Roseline Belizaire,Dick Chamla,Mohamed Janabi
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e277
10
Estimation of the Ebola outbreak size in the Democratic Republic of the Congo
刚果民主共和国埃博拉疫情规模估算
Ruth McCabe,Lennox Ebbarnezh,Solome Okware,Richard Fotsing,Etien Koua,Paul Mbaka,Adelard Lofungola,Dav M Ebengo,Placide K Mbala,Tania T Bishola,Christian M Ibolobolo,Herman M Matondo,Jean-Clement M Sibo,Sabine L van Elsland,Martina McMenamin,Neil M Ferguson,Olivier le Polain de Waroux,Anne Cori
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e279
Corrections（勘误）
11
Correction to Lancet Infect Dis 2020; 20: 1204–14
《柳叶刀·传染病》2020年；20卷：1204–14页勘误
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
12
Correction to Lancet Infect Dis 2023; 23: 1370–82
《柳叶刀·传染病》2023年；23卷：1370–82页勘误
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
13
Correction to Lancet Infect Dis 2024; 24: 775–82
《柳叶刀·传染病》2024年；24卷：775–82页勘误
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
14
Correction to Lancet Infect Dis 2026; 26: 343–61
《柳叶刀·传染病》2026年；26卷：343–61页勘误
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
15
Correction to Lancet Infect Dis 2025; published online March 18. https://doi.org/10.1016/S1473-3099(26)00059-9
《柳叶刀·传染病》2025年在线发表勘误，2025年3月18日
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
16
Correction to Lancet Infect Dis 2026; published online March 23. https://doi.org/10.1016/S1473-3099(26)00058-7
《柳叶刀·传染病》2026年在线发表勘误，2026年3月23日
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
17
Correction to Lancet Infect Dis 2026; published online March 31. https://doi.org/10.1016/S1473-3099(26)00063-0
《柳叶刀·传染病》2026年在线发表勘误，2026年3月31日
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e281
18
Correction to Lancet Infect Dis 2026; published online April 17. https://doi.org/10.1016/S1473-3099(26)00144-1
《柳叶刀·传染病》2026年在线发表勘误，2026年4月17日
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e282
19
Correction to Lancet Infect Dis 2026; published online April 28. https://doi.org/10.1016/S1473-3099(26)00137-4
《柳叶刀·传染病》2026年在线发表勘误，2026年4月28日
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e282
Newsdesk（新闻瞭望）
20
Hantavirus outbreak on cruise ship kills three
游轮汉坦病毒疫情致3人死亡
Tony Kirby
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e283
21
New WHO prequalifications signal hope for malaria
世卫组织新增预认证药品为疟疾防治带来希望
Sanjeet Bagcchi
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e284
22
New partnership to support TB vaccine implementation
全新合作项目助力结核病疫苗落地推广
Manjulika Das
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e285
23
Updated Global Action Plan on Antimicrobial Resistance
新版全球抗微生物药物耐药性行动计划
Timothy Jesudason
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e286
24
Update on the Ebola virus outbreak in DR Congo
刚果民主共和国埃博拉病毒疫情最新进展
Talha Burki
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e287
25
Research in brief
研究简报
Priya Venkatesan
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e288
Obituary（讣告）
26
Dame Bridget Ogilvie
布里吉特·奥格尔维女爵士
Udani Samarasekera
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p656
Profile（人物专访）
27
Sabiha Essack—helping Africa lead the fight against AMR
萨比哈·埃萨克——助力非洲主导抗微生物耐药性攻坚
Tony Kirby
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p657
Media Watch（媒体观察）
Film（影视）
28
Challenging the stigma around leprosy
消除麻风病相关社会污名
Sanjeet Bagcchi
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p658
Articles（论著）
29
Survival trends in patients with difficult-to-treat, antibiotic-resistant, Gram-negative infections in the era of next-generation antibiotics in the USA: a retrospective cohort study
新一代抗生素时代美国难治性耐药革兰阴性菌感染患者生存趋势：一项回顾性队列研究
Morgan K Walker,Christina Yek,Sadia Sarzynski,Sarah Warner,Anthony D Harris,Jonathan D Baghdadi,Katherine E Goodman,John H Powers III,Michael Klompas,Chanu Rhee,Bruce Swihart,Sameer S Kadrifor the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI)
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p659
30
Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study
重症监护室耳念珠菌定植患者念珠菌血症预测AURIS评分构建与验证：双中心回顾队列研究
Victor Garcia-Bustos,Francesc Puchades,Fernando Alonso-Ecenarro,Marta Dafne Cabanero-Navalon,Alba Ruiz-Gaitán,Javier Pemán,Miguel Salavert,María Tasias,Eva Calabuig,Remedio Guna,Carolina Ferrer-Gómez,María Pilar Ortega-García,Vicente Abril
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p671
31
Double-dose azithromycin mass drug administration, facial cleanliness, and fly control measures for trachoma control in Oromia, Ethiopia (Stronger SAFE): a cluster-randomised controlled trial
埃塞俄比亚奥罗米亚地区双倍剂量阿奇霉素群体给药、面部清洁与灭蝇综合沙眼防控方案（强化SAFE策略）：整群随机对照试验
Anna Last,Oumer Shafi Abdurahman,Katie Greenland,Ailie Robinson,Edao Sinba Etu,Robert Butcher,Meseret Guye,Demitu Legesse,Kedir Temam Nuri,Gemeda Shuka,Munira Haji-Mohammed Yusuf,Gaddisa Dheressa,Gebeyehu Dumessa,Haile Abera,Mesfin Bekele,Melese Akalu,Mesfin Tadesse,Dereje Adugna Kumsa,Fikre Seife Gebretsadik,Claire Collin,Alexandra Czerniewska,Bart Versteeg,Esmael Habtamu,Sarity Dodson,Aida Abashawl,Wondu Alemayehu,Anthony W Solomon,Helen A Weiss,James G Logan,David Macleod,Matthew J Burton
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p680
32
Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, randomised controlled trial
无钩虫感染健康成人接种吸附于氢氧化铝佐剂的Na-GST-1疫苗联合不同Toll样受体激动剂的人体可控感染模型Ⅱ期双盲随机对照试验（美国）
Caroline K DiRosato,Elissa M Malkin,Sean M Lee,Guacyara Erwin,Lara Hoeweler,Larissa Scholte,Maria Elena Bottazzi,David I Pritchard,Peter J Hotez,Jeffrey M Bethony,David J Diemert
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p692
33
Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort
尼日利亚拉沙热幸存者出院后远期后遗症分析：LASCOPE前瞻性队列研究
Eva Guichard,Sylvain Juchet,Ijeoma Chukwudumebi Etafo,Béatrice Serra,Delphine Gabillard,Chukwuyem Abejegah,Abiodun Tolani Abidoye,Bimpe Oyegunle,Benjamin Séri,Alexandre Duvignaud,Jackson Katembo Vihundira,Denis Malvy,Marion Bérerd-Camara,Nelson Akinola Adedosu,Ayeni Olufunke Gbenga,Liasu Adeagbo Ahmed,Oladele Oluwafemi Ayodeji,Marie Jaspard
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p705
34
Evaluating dengue transmission dynamics in an endemic urban setting in Viet Nam: an index-household contact cohort study
越南登革热流行城区传播动力学评估：索引病例-家庭接触者队列研究
Lucy Masdin,James Ashall,Mai Kim Huynh,Joseph Biggs,Jody Phelan,Sonal Shah,Lien Thuy Le,Trieu Bao Nguyen,Hung Thai Do,Hien Anh Thi Nguyen,Thuy Thi Thu Nguyen,Duc Anh Dang,Chihiro Iwasaki,Michiko Toizumi,Marnix Van Loock,Guillermo Herrera-Taracena,Leen Vijgen,Freya Rasschaert,Liesbeth Van Wesenbeeck,Julius Clemence Hafalla,Oliver J Brady,Lay-Myint Yoshida,Stéphane Hué,Martin L Hibberd
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p714
35
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials
乌干达、尼泊尔含无细胞百日咳疫苗婴儿免疫程序优化研究（OptImms）：两项开放标签非劣效随机对照试验
Sanjeev M Bijukchhe,Natalie G Marchevsky,Freddie Kibengo,Arun K Sharma,Ruby Basi,Liberty Cantrell,Sachi Chuke,Benjamin Curtis,Dimitri A Diavatopoulos,Agnes Eordogh,Madhav C Gautam,Meeru Gurung,Gerco den Hartog,Hari P Kattel,Samir KC,Dominic Kelly,Sarah Kelly,Grace Li,Pratistha Maskey,Ella Morey,Yama F Mujadidi,Dora J Mulondo,Tryphena Nareeba,Mary Nyantaro,Anil R Ojha,Bhishma Pokhrel,Shristy Rajkarnikar,Andrew Roberts,Sonu Shrestha,Gaby Smits,Surya B Thapa,Fiona Van der Klis,Merryn Voysey,Sudha Basnet,Alison M Elliott,Xinxue Liu,Shrijana Shrestha,Andrew J Pollardon behalf of the OptImms Nepal and Uganda teams
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p726
36
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial
美国50岁及以上健康成人31价肺炎球菌结合疫苗（VAX-31）安全性、耐受性与免疫原性Ⅰ/Ⅱ期双盲阳性对照平行分组剂量爬坡随机临床试验
James Wassil,Jeff Fairman,Carlos A Fierro,James Clark,Sean Bennett,Derek Johnson,Qin Jiang,Thi-Sau Migone,Alexandra Paschenko,Jakub K Simon,Steve Lamola,Maggie Sisti
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：p739
Review（综述）
37
Accelerating research and development of new vaccines against tuberculosis: 5-year progress on the global roadmap
加速新型结核病疫苗研发：全球路线图五年进展总结
Elly van Riet,Björn Corleis,Birgitte K Giersing,Mark Hatherill,Erlina Burhan,Waasila Jassat,Richard G White,David Lewinsohn,Frank Cobelens
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e289
38
Best practice guidelines for viral hepatitis service delivery in prisons
监狱病毒性肝炎规范化诊疗最佳实践指南
Yumi Sheehan,Akhil Garg,Julia Sheehan,Nonso Maduka,Frederick L Altice,Filipa Alves da Costa,Sean Cox,Ahmed M Elsharkawy,Ehab Salah,Mark Stoové,Lara Tavoschi,Alexander J Thompson,Karla Thornton,Andrew R Lloyd,Joaquín Cabezas,Matthew J Akiyama,Nadine Kronfli
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e302
Personal View（个人观点）
39
Post-tuberculosis lung disease: a case definition for use in research studies
结核后肺病：适用于科研的病例定义标准
Gregory P Bisson,Brian Allwood,Anthony Byrne,Gunar Günther,Celso Khosa,Neelima Navuluri,Rebecca Nightingale,Ingrid Schoeman,Marieke M van der Zalm,Jamilah Meghji,Sara Auld
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e315
Grand Round（大查房）
40
Management of critical illness in an adolescent caused by highly pathogenic avian influenza A(H5N1) virus infection in British Columbia, Canada
加拿大不列颠哥伦比亚省高致病性甲型H5N1禽流感病毒感染青少年危重症诊疗
Elspeth MacBain,Ashraf Znait,Linda Edwards,Agatha Jassem,Vilte E Barakauskas,Kevin C Harris,Sarah Lohrenz,Sareh Zahedieh,Nathalie Bastien,Charlene Ranadheera,Cherry Mammen,Roxana Azma,Audi Setiadi,Jonathan H Rayment,Nicolas Mourad,Ryaan El-Andari,Timothy M Uyeki,Lynne Li,Ashley Roberts,Muhieldin A Muhieldin,David M Goldfarb
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e326
Clinical Picture（临床图鉴）
41
Disseminated herpes zoster with hepatic necrosis in a patient with newly diagnosed HIV
初诊艾滋病患者播散性带状疱疹合并肝坏死
Shinya Hasegawa,Frida Teran-Garza,Jeffery L Meier
The Lancet Infectious Diseases. Jul 2026，Vol 26(7)：e335
THE LANCET Infectious Diseases. Volume 26Number 8
柳叶刀·传染病学26卷 8期
https://www.thelancet.com/journals/laninf/issue/current
Editorial（社论）
1
Our twenty-five year journey
二十五载发展历程
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p751
Comment（述评）
2
Sense and susceptibility: predicting influenza dynamics from immune landscapes
感知与易感性：基于免疫图谱预测流感流行动态
C Jessica E Metcalf,Wakinyan Benhamou,Oliver G Spacey,Jasmine Wang
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p752
3
New chapter in rabies vaccine development
狂犬病疫苗研发迈入新阶段
Leo G Visser
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p753
4
Clinical trial priorities, adaptive strategies, and equitable partnerships for the Bundibugyo Ebola outbreak
本迪布焦埃博拉疫情的临床试验重点、适应性策略与公平合作模式
Jean B Nachega,Olivier Tshiani Mbaya,Sabue Mulangu,Morenike Oluwatoyin Folayan,Nicaise Ndembi,Francine Ntoumi,Edward J Mills,Salim S Abdool Karim,Alimuddin Zumla,Jean-Jacques Muyembe-Tamfum
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p755
5
Bundibugyo Ebola in DR Congo and Uganda: community-centred response must be operational, not rhetorical
刚果民主共和国与乌干达本迪布焦埃博拉疫情：以社区为核心的防控重在落地而非空谈
Placide Mbala-Kingebeni,Yap Boum,Mosoka P Fallah,Barthalomew Wilson,Marie-Roseline Belizaire,Nicole A Hoff,Armand Sprecher,Lisa E Hensley,Jason Kindrachuk,Anne W Rimoin
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p757
6
The Bundibugyo virus disease outbreak: a warning signal for risks to health workers
本迪布焦病毒病暴发：医护人员职业暴露风险预警
Nebiyu Dereje,Yap Boum,Kyeng Mercy,Marie-Roseline Belizaire,Tolbert Nyenswah,Justus Nsio,Pierre Zalagile Akilimali,Atek Kagirita,Ngashi Ngongo,Jean Kaseya
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p759
Correspondence（读者来信）
7
Rapid recruitment for a remote long COVID clinical trial
远程长新冠临床试验受试者快速招募
Julia Moore Vogel
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e268
8
Tuberculosis treatment with early detection
早筛导向的肺结核治疗
Aparna Prakash
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e269
9
The limb-saving power of bedside Gram staining
床旁革兰氏染色的保肢价值
Samadhi Patamatamkul
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e270
10
Keep antibiotics habitable: stewardship as climate mitigation
守护抗生素生态：抗菌药物管理助力环境风险缓解
Giovanni Mori
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e271
11
25 years of antibiotics: from desperate access to precision safety
抗生素应用25年：从迫切可及迈向精准安全
Jinlin Guo,Xinfeng Cai,Mi Zhou
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e272
12
The optimism in front of us
前路可期
Victor Naestholt Dahl
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e273
13
The importance of study volunteers in saving future lives
研究志愿者对守护大众健康的重要意义
Chuen-Yen Lau
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e274
14
Crossing the regulatory and clinical operational valley in antimicrobial resistance: from a start-up's perspective
跨越抗菌耐药领域监管与临床落地鸿沟：初创企业视角
Venu Gopal Jonnalagadda
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e275
15
A new era of hope: the impact of long-acting injectables for individuals ageing with childhood HIV
希望新时代：长效注射药物对儿童期感染HIV老龄患者的作用
Hayley T Berry,Jordan Jones,Richard Lueking,Stephanie E Kirk
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e276
16
A defining clinical moment during the COVID-19 pandemic in Nigeria
尼日利亚新冠疫情中标志性临床事件
Chizaram Onyeaghala
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e277
Corrections（勘误）
17
Correction to Lancet Infect Dis 2026; published online June 2. https://doi.org/10.1016/S1473-3099(26)00194-5
《柳叶刀·传染病》2026年6月2日在线刊发文章勘误，文献doi：10.1016/S1473-3099(26)00194-5
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e278
18
Correction to Lancet Infect Dis 2026; published online June 3. https://doi.org/10.1016/S1473-3099(26)00285-9
《柳叶刀·传染病》2026年6月3日在线刊发文章勘误，文献doi：10.1016/S1473-3099(26)00285-9
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e278
Newsdesk（新闻资讯）
19
Indigenous Australians see surge in diphtheria cases
澳大利亚原住民白喉病例激增
Tony Kirby
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e279
20
Trials of medical countermeasures to begin in DR Congo
刚果民主共和国启动医学应对手段临床试验
Esther Nakkazi
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e280
21
Rollout of lenacapavir begins in South Africa
南非正式推广莱那卡韦
Ed Holt
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e281
22
Cold-chain vehicles to support vaccination in Ecuador
冷链运输车辆助力厄瓜多尔疫苗接种工作
Sanjeet Bagcchi
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e282
23
2026 High-Level Meeting on HIV/AIDS
2026年艾滋病高级别会议
Talha Burki
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e283
24
Research in brief
科研快讯
Priya Venkatesan
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e284
Obituary（讣告）
25
Edward Pesanti
爱德华·佩桑蒂
Udani Samarasekera
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p762
Profile（人物专访）
26
Krutika Kuppalli—containing infectious disease outbreaks
克鲁蒂卡·库帕利：防控传染病疫情
Udana Samarasekera
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p763
27
Troy Grennan—getting anal cancer the attention it deserves
特洛伊·格伦南：推动肛门癌获得应有重视
Tony Kirby
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p764
Media Watch（媒体瞭望）
Book（书评）
28
The market for pox remedies
天花治疗药物市场
Talha Burki
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p765
Articles（论著）
29
Measuring population immunity against influenza using individual antibody titres: a multicountry, retrospective observational study
基于个体抗体滴度评估人群流感免疫水平：多国回顾性观察研究
Weijia Xiong,Xiaotong Huang,Tran Thi Nhu Thao,Nguyen Thi Le Thanh,Liping Peng,Ranawaka A P M Perera,Vicky J Fang,Bingyi Yang,Sook-San Wong,Nancy H L Leung,Sheena G Sullivan,Dennis K M Ip,Malik Peiris,Ted M Ross,Maciej F Boni,Benjamin J Cowling,Tim K Tsang
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p766
30
Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial
新加坡高频、低频接种青年人群中，高剂量重组流感疫苗对比标准剂量鸡胚培养、细胞培养流感疫苗的免疫原性：单中心随机对照双盲4期临床试验
Sheena G Sullivan,Xuan Ying Poh,Stephany Sanchez-Ovando,A Jessica Hadiprodjo,Louise Carolan,Yi Qing Chin,Suma Rao,Stephanie Sutjipto,Joseph Lim,Desiree Anthony,Sapna P Sadarangani,Ian G Barr,Barnaby Young,Annette Fox
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p778
31
Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial
英国婴儿缩短间隔4CMenB基础免疫程序的免疫原性、不良反应与安全性：多中心开放标签、评估者盲法4期随机对照试验
Natasha Thorn,Zsofia Danos,Nick J Andrews,Natalina Sutton,Katrina Cathie,Daniel Owens,Dominic Kelly,Fiona Shackley,Tim Scorrer,Charlotte Lea,Andrew Collinson,Thahmena Miah,Jonathan Lewis-Bridgeman,Jennifer Pearce,Ray Borrow,Jennifer Louth,Abigail Bell,Shamez N Ladhani,Paul T Heath
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p793
32
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study
美国65岁及以上医保参保人群中20价肺炎球菌结合疫苗针对全因结局在现实中的保护效力：回顾性队列研究
Amanda C Miles,Jelena Vojicic,Paula Peyrani,Summer Rosenstock,Huihua Li,Jeffrey T Vietri,Qi Yan,Alison E Randall,Xin Zhao,Wencheng Zhu,Bobby Zhao,Anan Zhou,Luis Jodar,Bradford D Gessner,Christian Theilacker,Jennifer C Moïsi,Paul Balmer,Lindsay R Grant,Alejandro Cane
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p807
33
Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational study
美国南加州开展暴露后预防后多西环素抗淋病疗效的持续性：回顾性病例阴性观察研究
Matan Yechezkel,David Helekal,Banshri Kapadia,Vennis Hong,Magdalena E Pomichowski,Iris Anne C Reyes,Gregg S Davis,Nicola F Müller,Yonatan H Grad,Sara Y Tartof,Joseph A Lewnard
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p819
34
Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial
接种RTS,S/AS01E疫苗后，环子孢子蛋白NANP重复序列、C端特异性IgG应答持续时间及其与保护力的关联：3期临床试验配套免疫观察研究
Maria Lara-Escandell,Lina Sánchez,Dídac Macià,Chenjerai Jairoce,Maxmillian Mpina,Hermann Sorgho,Selidji Todagbe Agnandji,David Dosoo,Ben Gyan,Marta Vidal,Alfons Jiménez,Robert Andrew Mitchell,Daniel Medina-Expósito,Laura Puyol,Rebeca Santano,Sheetij Dutta,Seth Owusu-Agyei,Kwaku Poku Asante,Halidou Tinto,Pedro Aide,Augusto Nhabomba,Benjamin Mordmüeller,Claudia Daubenberger,Ruth Aguilar,John Waitumbi,Gemma Moncunill,Carlota Dobaño
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p832
35
Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial
坦桑尼亚成人与儿童单次腺病毒载体狂犬病疫苗接种1年期安全性及免疫原性：一项正在开展的部分随机对照1b/2期临床试验中期结果
Adam J Ritchie,Omary Hassan,Nsiande Urasa,Paschal A Apanga,Rinter Kimathi,Wilmina F Kalinga,Ivanny M Mtaka,Reward G Lyimo,Moshi Moshi Shabani,Francisco Orliacq,Adam Berg,ZhiQuan Xiang,Saumu Ahmed,Thabit Athuman,Hildegund C J Ertl,Ally Olotu,Alexander D Douglason behalf of the RAB002 study team
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p843
36
Diagnostic and prognostic accuracy of the Mycobacterium tuberculosis host response 3-gene cartridge among tuberculosis household contacts in Mozambique, Tanzania, and Zimbabwe: a prospective, longitudinal, diagnostic and prognostic accuracy cohort study
莫桑比克、坦桑尼亚、津巴布韦结核家庭密切接触者中结核宿主应答三基因检测试剂盒的诊断与预后效能：前瞻性纵向诊断预后队列研究
Leyla Larsson,Ioana Diana Olaru,Anna-Lisa Behnke,Edson T Marambire,Martha Chipinduro,Claire J Calderwood,Denise Banze,Alfred Mfinanga,Celina Nhamuave,Harieth L Mwambola,Kathrin Held,Rishi K Gupta,Lillian T Minja,Celso Khosa,Norbert Heinrich,Katharina Kranzeron behalf of the ERASE-TB consortium
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：p858
Review（综述）
37
Methodological quality assessment tool for observational studies comparing treatment effectiveness in infectious diseases: a Delphi consensus and application to studies on bloodstream infections due to carbapenem-resistant Enterobacterales
传染病疗效对比观察性研究方法学质量评价工具：德尔菲共识构建及耐碳青霉烯肠杆菌科菌血流感染研究应用
Giulia Zumbo,Martina Beltrami,Jose M Bravo-Ferrer,Belén Gutiérrez-Gutiérrez,Jesús Rodríguez-Bañothe ASSURE-ID group
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e285
38
Leptospirosis—clinical review and updates on therapeutics
钩端螺旋体病临床综述与治疗新进展
Nathaniel Lee,Takeshi Tanaka,Nobuo Koizumi,Charles Coughlan,Ana Ria Sayo,Koya Ariyoshi,Tansy Edwards,Chris Smith,Robin Bailey
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e294
Personal View（个人观点）
39
Transitioning to people-centred antimicrobial resistance surveillance
向以人为本的抗菌药物耐药监测模式转型
Direk Limmathurotsakul,Raheelah Ahmad,Elizabeth A Ashley,Rifat Atun,Rogier H van Doorn,Jyoti Joshi,Souha S Kanj,Janet Midega,Mirfin Mpundu,Paul Turner,Kamini Walia,Sharon J Peacock,Nicholas A Feaseyand the Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC)
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e308
40
The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward
贝达喹啉耐药肺结核危机迫近与可行解决路径
Pauline Howell,Jonathan Stillo,Anja Reuter,Tendai Nkomo,Carole D Mitnick,Lorenzo Guglielmetti,Kelly Curran,Richard E Chaisson,Jennifer Furin
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e314
Clinical Picture（临床图鉴）
41
Ignatzschineria larvae and Staphylococcus aureus bacteraemia secondary to cutaneous myiasis of the face
面部皮肤蝇蛆病继发伊格纳茨菌幼虫与金黄色葡萄球菌菌血症
Clive Martin Rodrigues,Jonathan Youngs,Anjaneya Bapat,Callan Strydom
The Lancet Infectious Diseases. Aug 2026，Vol 26(8)：e319
THE LANCET Infectious Diseases. Volume 26Number 9
柳叶刀·传染病学 26卷 9期
https://www.thelancet.com/journals/laninf/issue/current
Editorial（社论）
1
Oral carbapenem—a double‑edged sword?
口服碳青霉烯类药物：一把双刃剑？
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p871
Comment（述评）
2
Non‑sputum testing: an incomplete bridge across the tuberculosis diagnostic gap
非痰标本检测：弥合结核病诊断缺口尚不完美的桥梁
Adrienne E Shapiro
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p872
3
Beyond vaccines: closing the critical gap in diagnostics and therapeutics for outbreak response
疫苗之外：补齐疫情应对中诊断与治疗领域的关键短板
Tedros Adhanom Ghebreyesus,Jean Kaseya,Chikwe Ihekweazu,Vasee Moorthy,Mosoka Fallah,Shanelle Hall,Sylvie Briand
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p873
4
Reconsidering the rVSVΔG‑ZEBOV‑GP vaccine during the 2026 Bundibugyo virus outbreak
2026年本迪布焦病毒暴发期间对rVSVΔG‑ZEBOV‑GP疫苗的再思考
Krutika Kuppalli,Richard Lokudu,Andrew S Azman,Armand Sprecher,Gaston Musemakweli Komanda,Iza Ciglenecki,Manuel Albela,Deby Mukendi,Yap Boum,Jean B Nachega,Placide Mbala,Jean‑Jacques Muyembe‑Tamfum
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p875
Correspondence（通信）
5
Seasonal influenza versus COVID‑19 hospitalisation risk during the 2025–26 influenza season
2025‑2026流感季季节性流感与新型冠状病毒感染住院风险对比
Yan Xie,Taeyoung Choi,Ziyad Al‑Aly
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e321
6
Cefiderocol heteroresistance in NDM Enterobacterales
NDM阳性肠杆菌目细菌对头孢地尔的异质性耐药
Tugba Ozturk,Sarah Lohsen,Sarah W Satola,David S Weiss
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e323
7
Diagnostic performance of RADIONE for diagnosis of BDBV
RADIONE检测用于本迪布焦病毒的诊断效能
Tony Wawina‑Bokalanga,Adrienne Amuri‑Aziza,Koen Vercauteren,Daniel Mukadi‑Bamuleka,Christian Ngandu,Jason Kindrachuk,Pierre Akilimali,Jean‑Jacques Muyembe‑Tamfum,Placide Mbala‑Kingebenithe Ebola Research and Response Team
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e324
8
Real‑time epidemic intelligence in a public health emergency: the 2026 Bundibugyo virus outbreak
突发公共卫生事件下的实时疫情情报：2026年本迪布焦病毒暴发
Onesime Mbulayi,Pierre Akilimali,Ciara Judge,Bernardo Gutierrez,Patrick Mulu,Chistian M Ibolobolo,Jean‑Clement Sibo,Rossy Nkwele wa Nkwele,Matondo M Hermann,Leader Lawanga Ontshick,Daniel Mukadi,Benjamin Kanku,Eric Katanga,Kyeng Mercy,Joel Kosianza,Brian Ajong,Michel Muteba,Tania Bishola Tshitenge,Eddy Lusamaki,Romain Goldenberg,Linus Bengtsson,Ellie Bourgikos,Joseph L‑H Tsui,Cathal Mills,Moritz U G Kraemer,Samuel V Scarpino,Christian Ngandu,Dieudonne Mwamba Kazadi,Etien Koua,Olivier le Polain de Waroux,Placide Mbala‑Kingebeni,Dav M Ebengo
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e326
9
SARS‑CoV‑2 BA.3.2.2 is more evasive of neutralisation by plasma from young children
新冠病毒BA.3.2.2变异株更易逃逸幼儿血浆的中和作用
Madeline Wu,Hsiang Hong,Yicheng Guo,Kristin Daniel,Ryan Hisner,Marc C Johnson,Aubree Gordon,David D Ho,Ian A Mellis
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e328
10
Pseudovirus‑based analysis of host cell entry and vaccine‑induced neutralisation of Bundibugyo virus
基于假病毒分析本迪布焦病毒的宿主细胞入侵及疫苗诱导的中和效应
Markus Hoffmann,Aparna Shandheep,Andreas Pavlou,Katharina Rahmel‑Stein,My Linh Ly,Nianzhen Chen,Nicole Moor,Anna‑Sophie Moldenhauer,Christian Drosten,Ulrich Kalinke,Marylyn Martina Addo,Stefan Pöhlmann
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e330
11
Congolese hospital staff cohort admitted with infectious symptoms in the setting of the Bundibugyo virus outbreak, April and May 2026, Bunia, DR Congo
2026年4‑5月刚果（金）布尼亚，本迪布焦病毒暴发期间因感染症状入院的刚果医护人员队列
Patrick LaRochelle,Melinda McKnight,Ufoymungo Ucama Patrick,Musungufu Ambitapio Davin
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e332
Corrections（勘误）
12
Correction to Lancet Infect Dis 2020; 20: 37–59
勘误：Lancet Infect Dis 2020; 20: 37‑59
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e335
13
Correction to Lancet Infect Dis 2020; 20: 60–79
勘误：Lancet Infect Dis 2020; 20: 60‑79
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e335
14
Correction to Lancet Infect Dis 2026; published online June 30. https://doi.org/10.1016/S1473‑3099(26)00256‑2
勘误：Lancet Infect Dis 2026，6月30日在线发表。https://doi.org/10.1016/S1473‑3099(26)00256‑2
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e335
Newsdesk（新闻）
15
Sri Lanka battles major dengue outbreak
斯里兰卡应对登革热大规模暴发
Samaan Lateef
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e336
16
USA to end support of South Africa's HIV programmes
美国将终止对南非艾滋病项目的资助
Ed Holt
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e337
17
First rapid nucleic acid test for Bundibugyo virus
首款本迪布焦病毒快速核酸检测问世
Priya Venkatesan
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e338
18
New UN resolution links NTDs to human rights
联合国新决议将被忽视的热带病与人权相关联
Timothy Jesudason
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e339
19
Enrolment begins in the EBO‑PEP trial in DRC
刚果（金）EBO‑PEP临床试验启动受试者入组
Talha Burki
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e340
20
Research in brief
研究简报
Priya Venkatesan
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e341
Obituary（讣告）
21
Clarence James Peters
克拉伦斯·詹姆斯·彼得斯
Udani Samarasekera
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p878
Profile（人物专访）
22
Aalisha Sahukhan—strengthening public health responses
阿丽莎·萨胡坎——强化公共卫生应急处置能力
Tony Kirby
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p879
Media Watch（媒体观察）
Theatre（书评·戏剧）
23
Pride and solidarity
自豪与团结
Marco De Ambrogi
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p880
Articles（论著）
24
Expanding Xpert MTB/RIF Ultra and lateral flow urine lipoarabinomannan testing for diagnosis of tuberculosis among adults living with HIV admitted to hospitals in Tanzania and Mozambique (EXULTANT): a randomised controlled trial
在坦桑尼亚与莫桑比克住院HIV感染成人中推广Xpert MTB/RIF Ultra及尿脂阿拉伯甘露聚糖侧流检测用于结核病诊断（EXULTANT）：一项随机对照试验
Marta Cossa,Robert Ndege,Bindiya Meggi,Chacha Mangu,Vinzeigh Leukes,Issa Sabi,Celso Khosa,Bernard Kivuma,Dinis Nguenha,Friedrich Riess,Carlos Fernández‑Escobar,Laura de la Torre‑Perez,Patricia Manjate,Maja Weisser,Antonio Machiana,Craysophy Zachariah,Elisa Tagliani,Joanna Ehrlich,Julia Buech,Claudia Schacht,Sergi Sanz,Sunita Singh,Dorcas Mnzava,Samuel G Schumacher,Helen Cox,Leslie Scott,Nyanda Ntinginya,Katharina Kranzer,Morten Ruhwald,Adam Penn‑Nicholson,Alberto L Garcia‑Basteiroon behalf of the TB‑CAPT Consortium
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p881
25
Post‑mortem characterisation of pathogen‑specific causes of infection‑related deaths in African and south Asian neonates: a prospective, observational, multicentre study
非洲与南亚新生儿感染相关死亡的病原体特异性死因尸检分析：一项前瞻性、观察性多中心研究
Muntasir Alam,Kyu Han Lee,Vicky Baillie,Sana Mahtab,Afruna Rahman,Atique Iqbal Chowdhury,Julius Ojulong,Nega Assefa,Lola Madrid,Fentabil Getnet,Ayantu Mekonnen,Dickens Onyango,Victor Akelo,Florence Murila,Magdalene Kuria,Aggrey Igunza,Samba O Sow,Karen L Kotloff,Milagritos D Tapia,Adama Mamby Keita,Jane Juma,Inacio Mandomando,Marcelino Garrine,Rosauro Varo,Milton Kincardett,Ikechukwu Ogbuanu,Kazi Munisul Islam,Sulaiman Sannoh,Ima‑Abasi Bassey,Ejikeme Chukwuka Oham,Nelesh P Govender,Sithembiso Velaphi,Anthony Scott,Portia Mutevedzi,Beth Tippett Barr,Shams El Arifeen,Emily S Gurley,Quique Bassat,Cynthia G Whitney,Shabir A Madhithe CHAMPS Consortium
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p894
26
Performance of five mpox antigen‑based rapid diagnostic tests tested on lesion swabs from patients with suspected mpox from the Kinshasa province of DR Congo: a diagnostic accuracy study
5项猴痘抗原快速检测用于刚果（金）金沙萨省疑似猴痘患者皮损拭子样本的诊断效能：一项诊断准确性研究
Hugo Kavunga‑Membo,Hanesh Fru Chi,Devy M Emperador,Hugues Mirimo,Elie Ishara‑Nshombo,Marithe Mukoka,Raphael Lumembe,Michael Otieno,Mireille Muloki,Jean‑Claude Makangara‑Cigolo,Eddy Kinganda‑Lusamaki,Tony Wawina‑Bokalanga,Camille Escadafal,Kenneth Adea,Ana Hoxha,Rosamund F Lewis,Nicksy Gumede,Olga Ntumba‑Tshitenge,Richard Fotsing,Isabella Eckerle,Daniel Mukadi‑Bamuleka,Placide Mbala‑Kigenbeni,Emmanuel Agogo,Lorenzo Subissi
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p906
27
Immunogenicity and safety of a dose‑sparing inactivated poliovirus vaccine in infants in India: a phase 2/3, double‑blind, randomised controlled trial
印度婴儿减量接种灭活脊髓灰质炎疫苗的免疫原性与安全性：一项2/3期双盲随机对照试验
Prasad S Kulkarni,Sajjad A Desai,Suman Kanungo,Shanta Dutta,Madhu Gupta,Bheemisetty Srinivasa Chakravarthy,Sonali Palkar,Sushma Save,Renuka Munshi,Pradeep Nanjappa,Vijai Anand Babu Bangi,Sandeep Kumar Panigrahi,Sandesh Bharati,Parikshit Tyagi,Sunil Gairola,Jagdish K Zade,Sambhaji S Pisal,Rajeev M Dhere,Cyrus S Poonawalla,Anirudha Vyankatesh Poteyon behalf of the IPV‑01 Study Group
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p915
28
Sustained and indirect effects of PCV10 reduced‑dose schedules on pneumococcal carriage in Viet Nam: a long‑term follow‑up of a cluster‑randomised controlled trial
越南PCV10减量免疫程序对肺炎链球菌携带的持续及间接效应：一项整群随机对照试验的长期随访
Billy J Quilty,Michiko Toizumi,Hien Anh Thi Nguyen,Lien Thuy Le,Hoang Huy Le,Chihiro Iwasaki,Mizuki Takegata,Noriko Kitamura,Mohammad Monir Shah,Monica L Nation,Jason Hinds,Kevin van Zandvoort,Belinda D Ortika,Eileen M Dunne,Catherine Satzke,Hung Thai Do,Kim Mulholland,Duc‑Anh Dang,Stefan Flasche,Lay‑Myint Yoshida
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p925
29
Global and regional molecular epidemiology of HIV‑1 during 1990–2024: systematic review, global survey, and analysis of prevalence
1990‑2024年全球及区域HIV‑1分子流行病学：系统综述、全球调研与流行率分析
Ayisha Khalid,Lucy Gettins,Lauren Scullion,Xin Liu,Lily Li Lin Wei,Abednego N Masai,Philippe J Guerin,Kasim Allel,Joris HemelaarGlobal HIV Molecular Epidemiology Collaboration
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p939
30
Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real‑world multicentre retrospective registry study
马立巴韦治疗欧洲造血细胞移植受者临床意义明确的巨细胞病毒感染：一项多中心真实世界回顾性登记研究
Annalisa Paviglianiti,Per Ljungman,Rafael de la Camara,Gloria Tridello,Juana Schwartz,Nina Knelange,Arancha Bermudez Rodriguez,María Suárez‑Lledó,Johan Maertens,Maria Stamouli,Francis Ayuk,Candela Ceballos,Maria Huguet,Felipe Peña Muñoz,Pablo Granados,Alienor Xhaard,Jurgen Kuball,Chiara Nozzoli,Jan Styczynski,Dina Averbuchon behalf of the Infectious Diseases Working Party of the EBMT
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p956
31
Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high‑dose primaquine in Brazil (Curavivax): an open‑label, single‑centre, randomised clinical trial
巴西伯氨喹同步或延迟大剂量给药前提下，双氢青蒿素哌喹对比氯喹治疗非复杂性间日疟（Curavivax）：开放标签单中心随机临床试验
Djane C Baía‑da‑Silva,Kim Vinícius AmaralC Machado,Amanda Lia RebêloC Rabelo,Antônio AlcirleyC da Silva Balieiro,Antônio S LC Barbosa,Mônica Regina FariasC Costa,Vanderson S Sampaio,Gisely C Melo,Marcia A A Alexandre,Aline C C Alencar,Cristiana T Nascimento,Christiane Maria Prado Jerônimo,Mariana Souza Marcovski,Laila Rowena Albuquerque Barbosa,Cristiane Siqueira Valle,Thaís Alves Amaral Carrilho,JoséLuiz Fernandes Vieira,Marly Marques de Melo,Kelry Mazurega Oliveira Dinelly,Aretha Gomes Omena,José Diego Brito‑Sousa,Gilce Alves Barreiros,Yasmin Vieira Rocha,Aristóteles Comte Alencar Filho,Quique Bassat,Maria das Graças C Alecrim,André M Siqueira,Marcus V G Lacerda
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：p965
Review（综述）
32
The impact of clinical metagenomic testing on patient management: facts versus fantasy
临床宏基因组检测对患者诊疗的影响：现实与展望
Julianne R Brown,Charles Y Chiu,F Xavier López‑Labrador,Jutte J C de Vries
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e342
33
Artemisinin partial resistance at a crossroads: evidence for continental variation in Plasmodium falciparum clearance phenotypes
青蒿素部分耐药来到十字路口：恶性疟原虫虫体清除表型存在洲际差异的证据
Varun Hosangadi,David A Fidock
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e355
Personal View（个人观点）
34
Time to re‑evaluate combination antifungal therapy for invasive aspergillosis and other invasive mycoses
需重新评估侵袭性曲霉病及其他侵袭性真菌病的抗真菌联合治疗方案
Thomas S Harrison,Thomas J Walsh
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e366
Grand Round（临床病例研讨）
35
Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings
静脉注射免疫球蛋白治疗长新冠：1例临床及免疫学结果病例报告
Marta Camici,Eva Piano Mortari,Giulia Del Duca,Eleonora Cimini,Valentina Mazzotta,Chiara De Ponte,Ilaria Mastrorosa,Stefania Mazzotta,Carmela Pinnetti,Stefania Notari,Veronica Bordoni,Simona Gili,Giusi Prencipe,Fabrizio Maggi,Rita Carsetti,Enrico Girardi,Andrea Antinori,Chiara Agrati
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e373
Clinical Picture（临床图鉴）
36
Tularaemia after deer exposure in a vehicular collision
车辆碰撞接触鹿后罹患土拉菌病
Henning Gruell,Benedict Steffens,Daniela Jacob,Thorsten Wille,Leonard Poluschkin,Clara Lehmann,Philipp Schommers
The Lancet Infectious Diseases. Sep 2026，Vol 26(9)：e385
THE LANCET Infectious Diseases. Volume 26Number 10
柳叶刀·传染病学 26卷 10期
https://www.thelancet.com/journals/laninf/issue/current
Editorial（社论）
1
Counteracting the rise of antimicrobial resistance in Shigella
遏制志贺菌耐药性上升
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p975
Comment（述评）
2
A rifamycin-free regimen for shortened tuberculosis treatment
不含利福霉素类药物的短程结核病治疗方案
Guofang Deng,Liang Fu
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p976
3
Can better oral care reduce non-ventilator hospital-acquired pneumonia?
优化口腔护理能否降低非机械通气患者医院获得性肺炎发生率？
Catia Cilloniz,Michael Klompas
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p977
4
Mpox: virus expansion, evolution, and immune recognition
猴痘：病毒扩散、进化与免疫识别
Jason Kindrachuk,Anne W Rimoin
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p979
5
South Sudan's first 100 days of Bundibugyo Ebola readiness
南苏丹邦迪布焦埃博拉疫情首个百日防控准备工作
Dick Chamla,Marie Roseline Darnycka Belizaire,Arisekola Jinadu,Aggrey Bategereza,Isaias Fernandes,Stella Chunggong,Mohamed Janabi
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p980
Correspondence（读者来信）
6
Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1
新冠病毒变异株PQ.16.1.1与RK.1的抗体逃逸及受体结合特性
Peizhuo He,Yunwen Song,Caiwan Guo,Lingling Yu,Yuanling Yu,Fanchong Jian,Fei Shao,Yunlong Cao
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e386
7
Cross-reactive Bundibugyo antibody responses in Guinean survivors of Ebola virus and recipients of rVSVΔG-ZEBOV-GP (Ervebo) in an outbreak setting
疫情背景下几内亚埃博拉幸存者与Ervebo疫苗接种者体内邦迪布焦型埃博拉交叉反应抗体应答
Grace Hood,Joseph Akoi Bore,Dung Nguyen,Weston Struwe,Miles Carroll
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e388
Corrections（勘误）
8
Correction to Lancet Infect Dis 2024; 24: 763
《柳叶刀·传染病学》2024年第24卷763页勘误
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e390
9
Correction to Lancet Infect Dis 2026; published online July 7. [https://doi.org/10.1016/S1473-3099(26)00237-9](https://doi.org/10.1016/S1473-3099(26)00237-9)
《柳叶刀·传染病学》2026年7月7日在线发表文章勘误
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e390
10
Correction to Lancet Infect Dis 2026; 26: 832–42
《柳叶刀·传染病学》2026年第26卷832–842页勘误
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e390
Newsdesk（新闻专栏）
11
US measles elimination status likely to be lost as cases surge
麻疹病例激增，美国或将丧失麻疹消除认证
Tony Kirby
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e391
12
Merck's alimatravir licensing deal receives mixed response
默沙东alimatravir授权合作引发多方不同反响
Ed Holt
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e392
13
WHO updates guidelines for visceral leishmaniasis
世界卫生组织更新内脏利什曼病诊疗指南
Sanjeet Bagcchi
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e393
14
The Global Fund supports malaria response in DR Congo
全球基金助力刚果民主共和国疟疾防控
Manjulika Das
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e394
News（新闻）
15
Infection prevention and control gaps in Pakistan
巴基斯坦感染防控体系存在短板
Talha Burki
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e395
16
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e396
Obituary（讣告）
17
Bruce Ribner
布鲁斯·里布纳
Udani Samarasekera
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p984
Profile（人物专访）
18
Mahboubeh Hajiabdolbaghi—advancing ID care in Iran
马哈布贝·哈吉阿卜杜勒巴吉——推动伊朗传染病诊疗发展
Tony Kirby
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p985
Media Watch（媒体观察）
Books（书评）
19
Understanding the common cold
解读普通感冒
Emma Fabiani
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p986
Book（书评）
20
Taking on the silent killer
迎战无声杀手
Sanjeet Bagcchi
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p987
Articles（论著）
21
Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990–2023年肠道传染病与腹泻病全球疾病负担及其病原学特征：2023全球疾病负担研究系统分析
GBD 2023 Diarrhoeal Disease and Enteric Infectious Diseases Collaborators
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p988
22
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
奎博德匹司他+德拉马尼+贝达喹啉4个月方案治疗药物敏感性肺结核的有效性与安全性：一项多中心、开放标签、随机、概念验证、非劣效2b/c期临床试验
Rodney Dawson,Andreas H Diacon,Ebrahim Variava,Tumelo Moloantoa,William Brumskine,Tlhago Ngwanto,Ntokozo Zuma-Gwala,Ayman Osman,Mohammed Rassool,Jaclyn Ann Bennet,Yongge Liu,Raymond Xu,Wei Li,Simbarashe Takuva,Jeffrey Hafkin
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1010
23
Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia
口腔护理预防非机械通气医院获得性肺炎的效果（HAPPEN研究）：澳大利亚一项多中心阶梯整群随机试验
Nicole M White,Philip L Russo,Georgia Matterson,Katrina Browne,Allen C Cheng,Martin Kiernan,Peta E Tehan,Andrew J Stewardson,Nicholas Graves,Auxillia Madhuvu,Helen Rawson,Jenny Sim,Sonja Dawson,Julee McDonagh,Caroline Marshall,Elizabeth Orr,Douglas Johnson,Irani Thevarajan,Pakhi Sharma,Rhonda Wilson,Brett G Mitchell
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1022
24
Effect of a community-based behavioural intervention bundle to improve antibiotic use and patient management in Burkina Faso and DR Congo (CABU-EICO): a cluster-randomised controlled trial
布基纳法索与刚果民主共和国基于社区的综合行为干预措施优化抗生素使用与患者管理的效果（CABU-EICO研究）：一项整群随机对照试验
Brecht Ingelbeen,Daniel Valia,Bijou Mbangi,Esther van Kleef,Linda Campbell,Juste Stéphane Kouanda,César-Augustin Mambuku Khoso Muaka,Eric Wendpouiré Tiendrébeogo,Aminata Welgo,Veerle Bertels,Steven Declercq,Bram Riems,Marie Meudec,Edwin Wouters,Ben S Cooper,Delphin Mavinga Phanzu,Halidou Tinto,Marianne A B van der Sandeon behalf of the CABU-EICO Study Group
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1031
25
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
mRNA候选猴痘疫苗BNT166a的安全性与免疫原性：一项开放标签、剂量递增Ⅰ期人体临床试验
Frank Bähner,Saul N Faust,Leela R L Davies,Olga Blokhina,Donald M Brandon,William B Smith,Vengalil Krishna K Chatterjee,Hana Hassanin,Tara M Babu,Adam Zuiani,Susanne Steinhauser,Asaf Poran,Claire Brittain,Eric Mucker,Jay W Hooper,Robbert G van der Most,Pedro L Alonso,Özlem Türeci,Federico J Mensa,Uğur Şahin
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1045
26
Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
感染或接种疫苗后针对猴痘病毒Ia、Ib、IIb分支的中和抗体应答：一项多国观察性研究
Jameson Crandell,Raianna F Fantin,Leonardo Pereira de Araújo,Lauren Lawres,Lauren Pischel,Valter S Monteiro,Luciana Conde,Angelica C Kottkamp,Marie I Samanovic,Rita Cordeiro,Diana Póvoas,Mariana Melo,Terezinha M Castineiras,Andre M Vale,Inci Yildirim,Mark J Mulligan,Leonardo Augusto de Almeida,Saad B Omer,Camila H Coelho,Carolina Lucas
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1058
27
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
冈比亚不同年龄健康儿童接种黄热病加强针的安全性与免疫原性：一项开放标签、非随机、单中心Ⅲ期疫苗临床试验
Caitlin Pley,David J Jeffries,Ebrima Kanteh,Julia Strandmark,Aru Kumba Baldeh,Mam Nabou Leigh,Peter Ndow,Ed Clarke,Beate Kampmann
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1070
28
Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons
托珠单抗用于重症汉坦病毒肺综合征治疗：MEURI病例系列及对照分析
Fernando Tortosa,Germán Santamaría,Rodrigo Bustamante,Martín Alberto Ragusa,Ayelén Iglesias,Yesica Espasandin,Ariel Izcovich
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：p1079
Review（综述）
29
Expert consensus on case definitions in human loiasis: a Delphi study
人罗阿丝虫病病例定义专家共识：德尔菲法研究
Luzia Veletzky,Spinello Antinori,Sabine Bélard,Marielle Bouyou,Emmanuel Bottieau,Jérémy T Campillo,Cédric B Chesnais,Fernando de la Calle-Prieto,Federico Gobbi,Marc P Hübner,Amy D Klion,Pia Michelitsch,Andreas Neumayr,Tamara Nordmann,Thomas B Nutman,Fernando Salvador,Stephen D Vaughan,Michael Ramharter,Francesca Tamarozzi
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e397
30
A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models
尼帕病毒病流行病学参数、疫情暴发及数学模型系统综述
Tristan Naidoo,Christian Morgenstern,Patrick Doohan,Rhys Earl,Thomas Rawson,Richard J Sheppard,Joseph T Hicks,Sreejith Radhakrishnan,Rob Johnson,Anna-Maria Hartner,Lorenzo Cattarino,Kelly McCain,Anna Vicco,Natsuko Imai-Eaton,Sabine van Elsland,Anne Cori,Ruth McCabe,Sangeeta Bhatiathe Pathogen Epidemiology Review Group
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e409
Personal View（个人观点）
31
Understanding and exploiting superspreading to disrupt Mycobacterium tuberculosis transmission
认识并利用超级传播现象阻断结核分枝杆菌传播
Tyler S Brown,Kristin Nelson,Stephen Kissler,Leo Martinez,C Robert Horsburgh,Laura F White,Barun Mathema,Karen R Jacobson
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e423
Grand Round（大查房）
32
Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime–zidebactam alongside phage therapy in the USA
钙性尿毒症性小动脉病合并产NDM-1铜绿假单胞菌感染：美国头孢吡肟-齐德巴坦联合噬菌体治疗首次应用经验
Erlinda R Ulloa,Daniel Jaffurs,M Tuan Tran,Carol Lin,Hung Tran,Dorian Chan,Ali Nael,Sagar U Nigwekar,Mikeljon P Nikolich,Daria Van Tyne
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e433
Clinical Picture（临床图鉴）
33
Lymphoma-like endoscopic appearance of lymphogranuloma venereum
性病性淋巴肉芽肿内镜下淋巴瘤样表现
Takumi Wada,Mariko Kobayashi,Kiichiro Tsuchiya
The Lancet Infectious Diseases. Oct 2026，Vol 26(10)：e444
疫苗微生物疗法临床研究
100 项与 利福霉素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 旅行者腹泻 | 美国 | 2018-11-16 | |
| 痢疾 | 芬兰 | 2018-11-04 | |
| 肺结核 | 英国 | 2000-02-01 | |
| 革兰氏阳性细菌感染 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床2期 | 比利时 | 2017-12-18 | |
| 腹泻型肠易激综合征 | 临床2期 | 德国 | 2017-12-18 | |
| 腹泻型肠易激综合征 | 临床2期 | 意大利 | 2017-12-18 | |
| 腹泻型肠易激综合征 | 临床2期 | 西班牙 | 2017-12-18 | |
| 憩室炎 | 临床2期 | 德国 | 2013-08-01 | |
| 盲袢综合征 | 临床2期 | 美国 | - | |
| 梭菌感染 | 临床2期 | 墨西哥 | - | |
| 梭菌感染 | 临床2期 | 南非 | - | |
| 梭菌感染 | 临床2期 | 土耳其 | - | |
| 溃疡性结肠炎 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | - | 18 | 積積範鑰憲鬱觸願夢鹽(醖糧衊蓋蓋襯糧簾製夢) = including diarrhea-predominant irritable bowel syndrome, hepatic encephalopathy 鏇窪夢襯製鹽簾糧醖鑰 (獵積齋齋網繭餘製醖蓋 ) | 积极 | 2021-02-06 | ||
N/A | - | - | 醖鹽網齋築遞窪構繭憲(淵獵願廠窪鹹範顧壓簾) = 願鏇鑰鏇顧齋壓醖鏇鬱 獵遞獵廠鑰簾鹹鏇壓積 (簾選繭鑰壓積餘獵夢簾 ) | - | 2019-10-21 | ||
醖鹽網齋築遞窪構繭憲(淵獵願廠窪鹹範顧壓簾) = 襯齋願膚鏇窪鹹蓋鑰鹹 獵遞獵廠鑰簾鹹鏇壓積 (簾選繭鑰壓積餘獵夢簾 ) | |||||||
临床3期 | 835 | (Group A) | 鬱網願廠壓鬱選鬱膚齋(齋築選鹹艱觸鬱觸窪淵) = 獵製鬱鏇蓋艱鬱艱蓋餘 廠壓鏇鹹壓構糧衊顧鏇 (願餘膚鹽繭糧餘簾憲壓, 簾獵艱醖夢遞願糧獵膚 ~ 構壓夢範壓淵積膚網糧) 更多 | - | 2019-02-27 | ||
(Group B) | 鬱網願廠壓鬱選鬱膚齋(齋築選鹹艱觸鬱觸窪淵) = 鹹衊鏇鑰構遞壓憲鬱夢 廠壓鏇鹹壓構糧衊顧鏇 (願餘膚鹽繭糧餘簾憲壓, 範網鹹壓繭齋醖齋積夢 ~ 選餘艱築餘壓觸鏇選艱) 更多 | ||||||
临床2期 | 40 | (400 mg Rifamycin SV Dosage) | 夢網積範範壓窪廠選簾(壓淵鬱製遞網糧膚遞繭) = 網構衊觸簾餘繭簾範繭 鹽鑰簾鹽積鹽艱壓鬱鏇 (構顧衊鏇襯網觸齋顧築, 12.1) 更多 | - | 2018-10-09 | ||
(800 mg Rifamycin SV Dosage) | 夢網積範範壓窪廠選簾(壓淵鬱製遞網糧膚遞繭) = 艱齋醖繭夢顧蓋顧鏇齋 鹽鑰簾鹽積鹽艱壓鬱鏇 (構顧衊鏇襯網觸齋顧築, 12.3) 更多 | ||||||
临床3期 | 264 | Placebo (Placebo) | 簾糧齋壓醖遞艱壓齋窪(遞遞糧膚夢壓製餘製選) = 簾鹽築繭窪範窪醖鬱簾 顧構遞願膚繭鑰窪襯構 (窪範廠襯壓廠憲繭襯構, 膚衊鹽鏇鏇齋襯醖糧襯 ~ 繭築窪鬱觸憲範構壓廠) 更多 | - | 2018-04-10 | ||
(Rifamycin SV MMX) | 簾糧齋壓醖遞艱壓齋窪(遞遞糧膚夢壓製餘製選) = 選鬱鑰築鹹鹹夢餘顧淵 顧構遞願膚繭鑰窪襯構 (窪範廠襯壓廠憲繭襯構, 構窪觸顧蓋遞範願構夢 ~ 壓遞鹹製積鏇範齋築鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用